Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for MIRM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -44.25M
March 31, 2026 -228.76M
December 31, 2025 6.067M
September 30, 2025 39.68M
June 30, 2025 12.04M
March 31, 2025 -1.961M
December 31, 2024 -5.068M
September 30, 2024 3.984M
June 30, 2024 -3.803M
March 31, 2024 15.21M
December 31, 2023 -16.62M
September 30, 2023 -18.22M
June 30, 2023 -2.331M
March 31, 2023 -33.77M
December 31, 2022 -34.27M
Date Value
September 30, 2022 -26.02M
June 30, 2022 -20.17M
March 31, 2022 -39.67M
December 31, 2021 -33.15M
September 30, 2021 -34.20M
June 30, 2021 -40.20M
March 31, 2021 -25.21M
December 31, 2020 -36.28M
September 30, 2020 -17.45M
June 30, 2020 -16.99M
March 31, 2020 -18.35M
December 31, 2019 -13.70M
September 30, 2019 -15.22M
June 30, 2019 -8.017M
March 31, 2019 -2.426M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Incyte Corp. 507.66M
Insmed, Inc. -88.83M
Alnylam Pharmaceuticals, Inc. 326.72M
BioMarin Pharmaceutical, Inc. 168.11M
Ionis Pharmaceuticals, Inc. 565.53M